يعرض 1 - 10 نتائج من 20 نتيجة بحث عن '"bcd-085"', وقت الاستعلام: 0.92s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

    المؤلفون: V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva

    المصدر: Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)

    مصطلحات موضوعية: netakimab, bcd-085, monoclonal antibody, interleukin 17a, ankylosing spondylitis, axial spondyloarthritis, Diseases of the musculoskeletal system, RC925-935

    وصف الملف: electronic resource

    Relation: https://rsp.mediar-press.net/rsp/article/view/2925; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492

    URL الوصول: https://doaj.org/article/7a1a0bd45df54172a1cd35efba011387

    Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial

    المؤلفون: Sh. Erdes, V. I. Mazurov, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, E. V. Zonova, D. G. Krechikova, T. V. Plaksina, O. V. Reshetko, S. A. Smakotina, P. А. Shesternya, I. G. Gordeev, T. G. Makulova, T. V. Povarova, T. A. Raskina, N. F. Soroka, A. M. Pristrom, E. V. Kunder, Yu. V. Usacheva, E. Yu. Stukalina, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov

    المصدر: Научно-практическая ревматология, Vol 57, Iss 6, Pp 668-677 (2019)

    مصطلحات موضوعية: ankylosing spondylitis, radiographic axial spondyloarthritis, bcd-085, interleukin 17a inhibitor, Diseases of the musculoskeletal system, RC925-935

    وصف الملف: electronic resource

    Relation: https://rsp.mediar-press.net/rsp/article/view/2804; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492

    URL الوصول: https://doaj.org/article/d4904fdfb8d74d86b07500bfba5201ae

    Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

    المؤلفون: A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, V. R. Khairutdinov, M. M. Kokhan, A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva, R. A. Ivanov

    المصدر: Vestnik Dermatologii i Venerologii, Vol 95, Iss 3, Pp 54-64 (2019)

    مصطلحات موضوعية: psoriasis, treatment, genetic engineering biological preparations, bcd-085, netakimab, efficacy, safety, immunogenicity, Dermatology, RL1-803

    وصف الملف: electronic resource

    Relation: https://www.vestnikdv.ru/jour/article/view/499; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294

    URL الوصول: https://doaj.org/article/37963b61b86444bb812f998927a4eb67

    Full Text Finder
    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

    المؤلفون: A. A. Kubanov, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, E. V. Sokolovskiy, M. M. Kokhan, A. V. Artemyeva, E V. Chernyaeva, R. A. Ivanov

    المصدر: Vestnik Dermatologii i Venerologii, Vol 95, Iss 2, Pp 15-28 (2019)

    مصطلحات موضوعية: psoriasis, monoclonal antibody against il-17, biologics, pasi 75, bcd-085, netakimab, Dermatology, RL1-803

    وصف الملف: electronic resource

    Relation: https://www.vestnikdv.ru/jour/article/view/480; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294

    URL الوصول: https://doaj.org/article/4007b553226b4cd19f7d282f1ce493c9

    Full Text Finder
    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

    المؤلفون: A. L. Bakulev

    المصدر: Vestnik Dermatologii i Venerologii, Vol 94, Iss 5, Pp 26-32 (2019)

    مصطلحات موضوعية: psoriasis, comorbid conditions, therapy, genetically engineered biologic preparations, bcd-085, efficacy, safety, immunogenicity, Dermatology, RL1-803

    وصف الملف: electronic resource

    Relation: https://www.vestnikdv.ru/jour/article/view/436; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294

    URL الوصول: https://doaj.org/article/6fa3806c4a314e5aa97cf7856517aaba

    Full Text Finder
    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

    المؤلفون: A. V. Samtsov, V. R. Khairutdinov, A. L. Bakulev, A. A. Kubanov, A. E. Karamova, A. V. Artem’eva, T. V. Korotaeva

    المصدر: Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018)

    مصطلحات موضوعية: psoriasis, monoclonal antibody against interleukin-17, biological therapy, pasi 75, bcd-085, Dermatology, RL1-803

    وصف الملف: electronic resource

    Relation: https://www.vestnikdv.ru/jour/article/view/344; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294

    URL الوصول: https://doaj.org/article/ad95b195b540473996348322541ef657

    Full Text Finder
    أضف إلى المفضلة
  7. 7
    Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

    المؤلفون: N. Soroka, E. S. Zhugrova, S A Lapshina, D. G. Krechikova, E. P. Ilivanova, T. V. Plaksina, O B Nesmeyanova, E. Kunder, A. M. Pristrom, Diana Abdulganieva, O. V. Antipova, T. V. Kropotina, O. A. Tciupa, Inna Gaydukova, Elena A Smolyarchuk, I. G. Gordeev, Pavel Shesternya, V. V. Tyrenko, Mazurov Vi, Sh F Erdes, Tatiana Dubinina, T. V. Povarova, A. Eremeeva, A. V. Strelkova, A. Kastanayan

    المصدر: Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)

    مصطلحات موضوعية: 0301 basic medicine, bcd-085, medicine.medical_specialty, Every Two Weeks, Immunology, Diseases of the musculoskeletal system, Neutropenia, Placebo, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, ankylosing spondylitis, Clinical endpoint, medicine, Immunology and Allergy, Adverse effect, BASDAI, 030203 arthritis & rheumatology, Ankylosing spondylitis, business.industry, axial spondyloarthritis, medicine.disease, Clinical trial, interleukin 17a, 030104 developmental biology, RC925-935, monoclonal antibody, business, netakimab

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1bf23545fe52209a18611f1b084724b
    https://rsp.mediar-press.net/rsp/article/view/2925

    أضف إلى المفضلة
  8. 8
    Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext

    المؤلفون: Alexey A. Kubanov, S. I. Derbin, R. A. Ivanov, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, M. M. Kokhan, E. V. Chernyaeva, A. V. Artemyeva

    المصدر: Vestnik Dermatologii i Venerologii, Vol 95, Iss 3, Pp 54-64 (2019)

    مصطلحات موضوعية: bcd-085, safety, medicine.medical_specialty, Modern medicine, efficacy, immunogenicity, Clinical study, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Psoriasis, medicine, lcsh:Dermatology, In patient, Adverse effect, 030203 arthritis & rheumatology, treatment, business.industry, Immunogenicity, psoriasis, lcsh:RL1-803, medicine.disease, Regimen, Toxicity, genetic engineering biological preparations, business, netakimab

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb1fa007ed590f96614f2ec9eb02d33
    https://www.vestnikdv.ru/jour/article/view/499

    أضف إلى المفضلة
  9. 9
    Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

    المؤلفون: A. L. Bakulev

    المصدر: Vestnik Dermatologii i Venerologii, Vol 94, Iss 5, Pp 26-32 (2019)

    مصطلحات موضوعية: bcd-085, safety, Drug, medicine.medical_specialty, media_common.quotation_subject, comorbid conditions, efficacy, Disease, immunogenicity, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, lcsh:Dermatology, Medicine, genetically engineered biologic preparations, Severe psoriasis, Intensive care medicine, media_common, therapy, business.industry, Genetically engineered, psoriasis, lcsh:RL1-803, medicine.disease, Safety profile, 030220 oncology & carcinogenesis, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8083f24bca38ae53431248e97e38bfd5
    https://doi.org/10.25208/0042-4609-2018-94-5-26-32

    أضف إلى المفضلة
  10. 10
    Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

    المؤلفون: T. V. Korotaeva, A. E. Karamova, V. R. Khairutdinov, Alexey Samtsov, A. L. Bakulev, Antonina V. Artemeva, Alexey A. Kubanov

    المصدر: Vestnik Dermatologii i Venerologii, Vol 0, Iss 5, Pp 52-63 (2018)

    مصطلحات موضوعية: bcd-085, medicine.medical_specialty, Phases of clinical research, Placebo, Gastroenterology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Therapeutic index, Pharmacokinetics, Psoriasis, Internal medicine, medicine, lcsh:Dermatology, Adverse effect, 030203 arthritis & rheumatology, business.industry, psoriasis, lcsh:RL1-803, medicine.disease, Clinical trial, biological therapy, monoclonal antibody against interleukin-17, pasi 75, Interleukin 17, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1090fdf2e0b6eb85d0c846d1935d00
    https://www.vestnikdv.ru/jour/article/view/344

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء